...
首页> 外文期刊>American Journal of Kidney Diseases: The official journal of the National Kidney Foundation >Sodium bicarbonate therapy for prevention of contrast-induced nephropathy: a systematic review and meta-analysis.
【24h】

Sodium bicarbonate therapy for prevention of contrast-induced nephropathy: a systematic review and meta-analysis.

机译:碳酸氢钠疗法预防对比剂诱发的肾病:系统评价和荟萃分析。

获取原文
获取原文并翻译 | 示例

摘要

BACKGROUND: Optimal hydration measures to prevent contrast-induced nephropathy are controversial. STUDY DESIGN: We conducted a systematic review and meta-analysis using the MEDLINE database (1966 to January 2008), EMBASE (January 2008), and abstracts from conference proceedings. SETTING & POPULATION: Adult patients undergoing contrast procedures. SELECTION CRITERIA FOR STUDIES: Randomized controlled trials comparing intravenous hydration with sodium bicarbonate with hydration with intravenous normal saline for prevention of contrast-induced nephropathy. INTERVENTION: Hydration with intravenous sodium bicarbonate with or without N-acetylcysteine versus hydration with normal saline with or without N-acetylcysteine. OUTCOMES: Contrast-induced nephropathy, need for renal replacement therapy, and worsening of heart failure. RESULTS: Twelve trials (1,854 participants) were included. Sodium bicarbonate significantly decreased the risk of contrast-induced nephropathy (12 trials, 1,652 patients; odds ratio [OR], 0.46; 95% confidence interval [CI], 0.26 to 0.82; I2 = 55.9%) without a significant difference in need for renal replacement therapy (9 trials, 1,215 patients; OR, 0.50; 95% CI, 0.16 to 1.53; I2 = 0%), in-hospital mortality (11 trials, 1,640 patients; OR, 0.51; 95% CI, 0.15 to 1.69), or congestive heart failure compared with controls. Similar results were seen for the risk of contrast-induced nephropathy when sodium bicarbonate was compared with normal saline alone (OR, 0.39; 95% CI, 0.20 to 0.77), but not when sodium bicarbonate/N-acetylcysteine combination was compared with N-acetylcysteineormal saline combination (OR, 0.68; 95% CI, 0.34 to 1.37). A subgroup analysis limited to published trials showed similar results (OR, 0.26; 95% CI, 0.10 to 0.64; I2 = 63.3%), whereas unpublished studies showed a nonsignificant decrease (OR, 0.85; 95% CI, 0.46 to 1.57; I2 = 25.9%) in risk of contrast-induced nephropathy. LIMITATION: Publication bias and heterogeneity. CONCLUSION: Hydration with sodium bicarbonate decreases the incidence of contrast-induced nephropathy in comparison to hydration with normal saline without a significant difference in need for renal replacement therapy and in-hospital mortality. Larger studies analyzing patient-centered outcomes are needed.
机译:背景:预防对比剂引起的肾病的最佳补水措施是有争议的。研究设计:我们使用MEDLINE数据库(1966年至2008年1月),EMBASE(2008年1月)和会议记录摘要进行了系统的回顾和荟萃分析。地点和人口:接受造影剂检查的成年患者。研究的选择标准:随机对照试验比较了碳酸氢钠静脉水合作用和静脉生理盐水水合作用以预防造影剂诱发的肾病。干预:静脉注射碳酸氢钠加或不加N-乙酰半胱氨酸的水合与生理盐水加或不加N-乙酰半胱氨酸的水合。结果:造影剂引起的肾病,需要肾脏替代治疗和心力衰竭加重。结果:包括十二项试验(1,854名参与者)。碳酸氢钠可显着降低造影剂诱发的肾病的风险(12个试验,1,652例;优势比[OR]为0.46; 95%置信区间[CI]为0.26至0.82; I2 = 55.9%),但对肾脏替代疗法(9个试验,1,215例患者; OR,0.50; 95%CI,0.16至1.53; I2 = 0%),院内死亡率(11个试验,1,640例患者; OR,0.51; 95%CI,0.15至1.69 )或充血性心力衰竭。当将碳酸氢钠与单独的生理盐水进行比较时,对比剂诱发的肾病的风险观察到相似的结果(OR,0.39; 95%CI,0.20至0.77),但是当将碳酸氢钠/ N-乙酰半胱氨酸组合与N-进行比较时,则没有类似的结果。乙酰半胱氨酸/生理盐水的组合(OR为0.68; 95%CI为0.34至1.37)。仅限于已发表试验的亚组分析显示了相似的结果(OR,0.26; 95%CI,0.10至0.64; I2 = 63.3%),而未发表的研究显示,无显着降低(OR,0.85; 95%CI,0.46至1.57; I2 = 25.9%)患造影剂肾病的风险。限制:出版偏见和异质性。结论:与生理盐水水合相比,碳酸氢钠水合可降低造影剂诱发的肾病的发生率,而肾脏替代疗法和院内死亡率的需求无明显差异。需要更大的研究来分析以患者为中心的结果。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号